RBC Capital Downgrades Sage Therapeutics (SAGE) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts SAGE Hot Sheet
Price: $8.68 --0%
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 15
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 15
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams downgraded Sage Therapeutics (NASDAQ: SAGE) from Outperform to Sector Perform with a price target of $25.00 (from $71.00).
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $36.10 yesterday.
You May Also Be Interested In
- Morgan Stanley Downgrades BE Semiconductor (BESI:NA) (BESIY) to Equalweight
- Cheesecake Factory (CAKE) PT Raised to $80 at UBS
- Guggenheim Downgrades Avalo Therapeutics Inc. (AVTX) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
